Peptides DB
Research-centric peptide and protocol reference hub
Study 37 of 38Vosoritide literatureGenetics in medicine : official journal of the American College of Medical Genetics · RCT · Phase 22026

Vosoritide Treatment in Children with Hypochondroplasia: Three-Year Results from a Phase 2 Extension Trial.

Vosoritide treatment in children with hypochondroplasia showed sustained growth improvements over three years, but results should be interpreted cautiously due to the small sample size.

Read at Genetics in medicine : official journal of the American College of Medical GeneticsAdd to compare

Where it sits

this study against the rest of the vosoritide corpus
1
Preclinical
23
Observational
0
Open-label
6
Randomised · this one
8
Reviews

Summary and findings

This study measured the effects of vosoritide on growth in children with hypochondroplasia over three years. Thirteen participants who previously responded to treatment continued receiving daily subcutaneous vosoritide at a dose of 15 μg/kg/day. The study reported increases in height and annualized growth velocity.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Mean height SDS increased by 0.72 SD from Day 1 to Year 3, reaching -2.64±0.79 SD on the CDC growth charts.n=13Phase 22026

Abstract

The authors’ words, as Genetics in medicine : official journal of the American College of Medical Genetics supplied them

<h4>Purpose</h4>Vosoritide is a C-type natriuretic peptide analog approved for achondroplasia and under investigation for selected genetic causes of short stature. We previously reported the 12-months results of a phase 2 trial in children with hypochondroplasia (NCT04219007). Here, we report safety and efficacy outcomes from the three-year extension phase.<h4>Methods</h4>After completing a 6-month observation period followed by 12 months of daily subcutaneous vosoritide (15 μg/kg/day), participants with an increase in annualized growth velocity (AGV) >1.6 cm/year compared to baseline were eligible to continue in an open-label extension phase.<h4>Results</h4>Thirteen participants entered the extension phase and completed three years of treatment. Mean height SDS increased by 0.72 SD from Day 1 to Year 3, reaching -2.64±0.79 SD on the CDC growth charts. A similar increase was observed on the hypochondroplasia-specific charts (0.83 SD). Mean AGV increased from 4.27±0.70 cm/year at baseline to 7.24±0.80 cm/year at Year 1 and remained above baseline at Year 3 (6.13±1.27 cm/year). No new safety concerns were identified.<h4>Conclusion</h4>Vosoritide was associated with sustained improvements in growth in a selected cohort of initial good responders with hypochondroplasia. The treatment was well tolerated. Limitations of the extension study include selection bias and a small sample size.

Background

This paper addresses the long-term effects of vosoritide, a C-type natriuretic peptide analog, in children with hypochondroplasia. Previous studies have indicated short-term efficacy, but longer-term data are necessary to assess sustained benefits and safety. Understanding the impact of vosoritide on growth in this population is crucial for evaluating its potential role in treating genetic causes of short stature.

Methods

The study design involved an open-label extension phase following a 6-month observation period and 12 months of daily subcutaneous vosoritide at a dose of 15 μg/kg/day. The population consisted of children with hypochondroplasia who had shown an increase in annualized growth velocity greater than 1.6 cm/year compared to baseline. The primary outcome measures included changes in height SDS and annualized growth velocity over three years.

Results

The primary endpoint showed that mean height SDS increased by 0.72 SD from Day 1 to Year 3, reaching -2.64±0.79 SD. Mean annualized growth velocity increased from 4.27±0.70 cm/year at baseline to 7.24±0.80 cm/year at Year 1, and remained above baseline at Year 3 with a value of 6.13±1.27 cm/year. No new safety concerns were reported during the study.

Interpretation

These findings suggest that vosoritide may provide sustained improvements in growth metrics for children with hypochondroplasia, although the effect size may not be clinically significant given the small sample size. The lack of new safety concerns is a positive aspect, but the study's limitations, including selection bias and the small n of 13 participants, restrict the ability to generalize these results to a broader population. Further studies with larger cohorts are necessary to confirm these outcomes.

Key findings

  • Mean height SDS increased by 0.72 SD from Day 1 to Year 3, reaching -2.64±0.79 SD.
  • Mean AGV increased from 4.27±0.70 cm/year at baseline to 7.24±0.80 cm/year at Year 1 and remained at 6.13±1.27 cm/year at Year 3.
  • No new safety concerns were identified.

Limitations

  • small sample size of n=13
  • selection bias in participant eligibility
  • open-label design may introduce bias
  • no control group for comparison

Elsewhere in the Vosoritide corpus

BSex-specific risk profiles of drug-associated joint stiffness and deformity: a FAERS-based pharmacovigilance study with Canadian Vigilance Adverse Reaction Database validation.Clinical and experimental rheumatology · 2023 · vosoritide, ROR=125.78reviewAVosoritide Treatment in Children with Hypochondroplasia: Three-Year Results from a Phase 2 Extension Trial.Genetics in medicine : official journal of the American College of Medical Genetics · 2026 · Mean height SDS increased by 0.72 SD from Day 1 to Year 3, reaching -2.64±0.79 SD.HumanBAchondroplasia: From bone to bench to bedside an integrated review of medical and surgical management strategies.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2026 · Not reported in abstract.reviewBReal-world evidence of vosoritide treatment in children under 2 years of age with achondroplasia in Colombia: a cases seriesbiorxiv-preprint · 2026 · Mean age at last evaluation was 25.2 months (range 17–30 months).HumanBEvaluation of sleep-related breathing disorders and polysomnography findings in pediatric patients with achondroplasia.European journal of pediatrics · 2026 · n=49 · Median total AHI was 3.2 events/hour in children receiving vosoritide and 6.9 in those not receiving treatment (p=0.105).HumanBRetinal Structural and Microvascular Findings During Novel NPR-B-Targeted Vosoritide Therapy in Children with Achondroplasia.Journal of clinical medicine · 2023 · n=12 · p < 0.05 for nominal increases in RNFL thickness.Human